Combination therapy with GLP-1 receptor agonists and basal insulin: A systematic review of the literature

Diabetes, Obesity and Metabolism

Volumn 15, Issue 6, 2013, Pages 485-502

  Balena, R ^a   Hensley, I E ^a   Miller, S ^b   Barnett, A H ^c  

^a ELI LILLY AND COMPANY   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

GLP 1; Glycaemic control; Insulin therapy; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PLACEBO;

ACUTE PANCREATITIS; CLINICAL PRACTICE; DIABETIC PATIENT; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DRUG DOSE INTENSIFICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LONG TERM CARE; MULTICENTER STUDY (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84877633796     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12025     Document Type: Review

References (79)

1. Wysham CH. New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals. Postgrad Med 2010; 122: 52-60.
2. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 55: 1577-1596.
3. Abraira C, Henderson WG, Colwell JA et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 1998; 21: 574-579.
4. Hoerger TJ, Ahmann AJ. The impact of diabetes and associated cardiometabolic risk factors on members: Strategies for optimizing outcomes. J Manag Care Pharm 2008; 14: S2-S14.
5. Dodd AH, Colby MS, Boye KS, Fahlman C, Kim S, Briefel RR. Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004. Curr Med Res Opin 2009; 25: 1605-1613.
6. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004; 27: 17-20.
7. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
8. Monnier L, Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes Metab 2006; 32: 7-13.
9. Lipska KJ, Kosiborod M. Hypoglycemia and adverse outcomes: marker or mediator? Rev Cardiovasc Med 2011; 12: 132-135.
10. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010; 33: 1389-1394.
11. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57: 3169-3176.
12. Stonehouse AH, Holcombe JH, Kendall DM. Management of type 2 diabetes: the role of incretin mimetics. Exp Opin Pharmacother 2006; 7: 2095-2105.
13. Barnett AH, Burger J, Johns D et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007; 29: 2333-2348.
14. Rosenstock J, Fonseca V. Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse!. Diabetes Care 2007; 30: 2972-2973.
15. Drucker DJ, Buse JB, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
16. Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008; 14: 285-292.
17. Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
18. Marre M, Penfornis A. GLP-1 receptor agonists today. Diabetes Res Clin Pract 2011; 93: 317-327.
19. Christensen M, Knop FK, Vilsbøll T, Holst JJ. Lixisenatide for type 2 diabetes mellitus. Exp Opin Invest Drugs 2011; 20: 549-557.
20. Perry CM. Liraglutide: a review of its use in the management of type 2 diabetes mellitus. Drugs 2011; 71: 2347-2373.
21. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011; 13: 394-407.
22. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008; 24: 2943-2952.
23. Gentilella R, Bianchi C, Rossi A, Rotella CM. Exenatide: a review from pharmacology to clinical practice. Diabetes Obes Metab 2009; 11: 544-556.
24. Kahn SE. Clinical review 135: The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 4047-4058.
25. Fehse F, Trautmann M, Holst JJ et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 5991-5997.
26. Bunck MC, Diamant M, Corner A et al. One-year treatment with exenatide improves β-cell function, compared to insulin glargine, in metformin treated type 2 diabetes patients: a randomized, controlled trial. Diabetes Care 2009; 32: 762-768.
27. Bunck MC, Corner A, Eliasson B et al. Effects of exenatide on measures of β-cell function after 3years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011; 34: 2041-2047.
28. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
29. Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther 2012; 30: e146-e155.
30. Nauck MA, Meier JJ. Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells? Nat Rev Endocrinol 2011; 7: 193-195.
31. Linnebjerg H, Park S, Kothare PA et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008; 151: 123-129.
32. Astrup A, Rossner S, Van Goal L et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616.
33. Pharmaceuticals Inc A. BYETTA® exenatide injection [prescribing information]. San Diego, CA: Amylin Pharmaceuticals, Inc, 2011.
34. European Medicines Agency. 2011. Outcome of extension of indication application for for Victoza (liraglutide). Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/001026/WC500112831.pdf. Accessed 29 February 2012.
35. European Medicines Agency. 2012. Levemir Product Information. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000528/WC500036662.pdf. Accessed 29 February 2012.
36. Tzefos M, Olin JL. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus. Ann Pharmacother 2010; 44: 1294-1300.
37. Perfetti R. Combining basal insulin analogs with glucagon-like peptide-1 mimetics. Diabetes Technol Ther 2011; 13: 873-881.
38. Ryder REJ, Thong KY, Cull ML, Mills AP, Walton C. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits (Abstract 804). Diabetologia 2011; 54(Suppl 1): S326.
39. Anholm C, Frandsen H, Højgaard-Hansen EC, Vestergaard H, Madsbad S. Use of once daily liraglutide in type 2 diabetes: clinical practice and experiences from combination with oral antidiabetic drugs or insulin (Abstract 1142-P). Diabetes 2011; 60: A314.
40. Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes 2012; 6: 41-46.
41. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009; 31: 1511-1523.
42. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007; 13: 444-450.
43. Thong KY, Jose B, Sukumar N et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab 2011; 13: 703-710.
44. Pawaskar M, Li Q, Lee LJ, Reynolds M, Hoogwerf BJ. Clinical effectiveness of concomitant therapy with exenatide BID and basal insulin in patients with type 2 diabetes: a real-world analysis (Abstract P 1350). World Diabetes Congress. Dubai, United Arab Emirates: International Diabetes Federation, 2011.
45. Levin P, Wei W, Wang L et al. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes. Curr Med Res Opin 2012; 28: 439-446.
46. Levin PA, Mersey JH, Zhou S, Bromberger LA. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes. Endocr Pract 2012; 18: 17-25.
47. Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 2010; 103: 687-694.
48. Phillips S, Gulbranson N, Kabadi U. Marked improvement in glycemic control with exenatide (Byetta®) on addition to metformin, sulfonylurea and insulin glargine in type 2 diabetes mellitus (Abstract 2309-PO). Diabetes 2011; 60: A614.
49. Vithian K, Qureshi A, Chen B, Steer K. Exenatide replacing insulin in obese/overweight patients with type 2 diabetes; a district general hospital experience (Abstract P342). Diabet Med 2009; 24: 139-140.
50. Albu J, Raja-Khan N. The management of the obese diabetic patient. Prim Care 2003; 30: 465-491.
51. Davies M, Khunti K. Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine. Diabetes Obes Metab 2008; 10(Suppl 2): 42-49.
52. Buse JB, Bergenstal RM, Glass LC et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Int Med 2011; 154: 103-112.
53. Seino Y, Min KW, Niemoeller E, Takami A. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012; 14: 910-917.
54. Riddle M, Ahmann A, Basu A, Aroda V, Ratner R. Metformin+exenatide+basal insuiln vs metformin+placebo+basal insulin: reaching A1c <6.5% without weight-gain or serious hypoglycemia (Abstract 18-LB). Diabetes 2010; 59.
55. Blevins TC, Arakaki RF, Liljenquist DR et al. Once-daily basal insulin added to oral antihyperglycemic medications (OAMs) and exenatide (Ex) improves glycemic control in patients (Pts) with type 2 diabetes (T2D) (Abstract 19-LB). Diabetes 2012; 59.
56. Arakaki RF, Blevins TC, Liljenquist DR et al. Efficacy and safety of insulin lispro protamine suspension versus insulin glargine added to oral antihyperglycaemic medications and exenatide in patients with type 2 diabetes (Abstract 979). Diabetologia 2010; 53: S390-S391.
57. DeVries JH, Bain SC, Rodbard HW et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012; 35: 1446-1454.
58. Bain SC, DeVries JH, Seufert J et al. Adding insulin determir (IDet) to liraglutide and metformin improves glycaemic controls with sustained weight reduction and low hypoglycaemia rate: 52week results (Abstract 73). Diabetologia 2011; 54: S37.
59. Rosenstock J, DeVries JH, Seufert J et al. A new type 2 diabetes treatment paradigm: sequential addition of liraglutide to metformin and then basal insulin detemir (Abstract 276-OR). Diabetes 2011; 60: A76.
60. Rodbard H, DeVries JH, Bain SC, et al. Treatment intensification with insulin detemir does not compromise liraglutide-associated improvements in cardiovascular risk markers (Abstract P 1359). World Diabetes Congress. Dubai, United Arab Emirates: International Diabetes Federation, 2011.
61. Rachabattula H, Mukhtar RYA, Taylor PN, Robinson AM. Exenatide and insulin combination therapy in type 2 diabetes. Diabetes 2011; 60: A606(Abstract 2280-PO).
62. Pawaskar MD, Blickensderfer AL, Hoogwerf BJ, Quimbo R, Wade R. Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy. J Med Econ 2011; 14: 705-708.
63. Levin P, Wei W, Wang L, Damon D, Baser O. Clinical characteristics and outcomes in patients with type 2 diabetes (T2D) adding insulin glargine to exenatide or exenatide to insulin glargine in a US managed care setting. Diabetes 2011; 60: A266(Abstract 972-P).
64. Christofides EA, Boyle PJ, Johnson MT. Real world clinical experience with exenatide, a long term study on weight and A1C control. Diabetes 2009; 58: A154(Abstract 572-P).
65. Noel RA, Braun DK, Patterson RE, Bloomgren G. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32: 834-838.
66. Novo Nordisk Inc. Victoza® (liraglutide [rDNA origin] injection), solution for subcutaneous use [prescribing information]. Princeton, NJ: Novo Nordisk Inc, 2012.
67. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010; 33: 428-433.
68. Dore DD, Seeger JD. Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25: 1019-1027.
69. Wenten M, Gaebler JA, Hussein M et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med 2012; 29: 1412-1418.
70. Dore DD, Bloomgren GL, Wenten M et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011; 13: 559-566.
71. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33: 2349-2354.
72. Seshasai SR, Kaptoge S, Thompson A et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841.
73. Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 2011; 22: 189-197.
74. Elashoff M. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150-156.
75. Scottish Medicines Consortium. Exenatide, 5 micrograms & 10 micrograms, solution for injection, prefilled pen (Byetta®). Available from URL: http://www.scottishmedicines.org.uk/files/advice/exenatide_Byetta_FINAL_May_2012_for_website.pdf. Accessed 30 August 2012.
76. Palmer AJ, Roze S, Valentine WJ et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004; 20(Suppl 1): S5-S26.
77. Towse A. Should NICE's threshold range for cost per QALY be raised? Yes. BMJ 2009; 338: b181.
78. Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 2012; 14: 675-688.
79. Houser D, Christofides E. Real world clinical experience with exenatide, a long term study on weight and A1c control. Diabetes 2011; 60: A618(Abstract 2323-PO).